Nova Satra Dx Pte. Ltd., a Singapore based molecular diagnostics startup, raised USD$2.0m (SGD$2.8m) in funding.
Genting Bio Cellular Sdn Bhd (a wholly-owned subsidiary of Genting Berhad) made the investment. In conjunction with the funding, two directors nominated by Genting have joined Nova Satra’s board. In addition, a wholly-owned subsidiary of Genting Bio Cellular has acquired the exclusive right to distribute the test in Malaysia.
The company intends to use the funds for regulatory approvals and commercialization of its lead test, a non-invasive blood based diagnostic test for breast cancer.
Led by Kane Black, Chief Executive & Co-Founder, Nova Satra is committed to developing blood based diagnostic tests that provide early highly accurate detection of cancer.
Utilizing a University of Oxford developed epigenetic platform technology, the Nova Satra Breast Cancer test is an accurate blood based diagnostic test for breast cancer, that relies on highly stable DNA based targets as part of chromosomal signatures (AKA gene loops, chromosome domains, long range chromosomal
interactions), rather than other molecular diagnostic tests that rely upon unstable protein/RNA molecules.
The breast cancer test has recently completed multi centre Asian validation trials.